Global Novel Coronavirus (COVID-19) Vaccine Supply, Demand and Key Producers, 2023-2029
Page: 125
Published Date: 06 Sep 2023
Category: New Technology
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
The global Novel Coronavirus (COVID-19) Vaccine market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report studies the global Novel Coronavirus (COVID-19) Vaccine demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Novel Coronavirus (COVID-19) Vaccine, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Novel Coronavirus (COVID-19) Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Novel Coronavirus (COVID-19) Vaccine total market, 2018-2029, (USD Million)
Global Novel Coronavirus (COVID-19) Vaccine total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Novel Coronavirus (COVID-19) Vaccine total market, key domestic companies and share, (USD Million)
Global Novel Coronavirus (COVID-19) Vaccine revenue by player and market share 2018-2023, (USD Million)
Global Novel Coronavirus (COVID-19) Vaccine total market by Type, CAGR, 2018-2029, (USD Million)
Global Novel Coronavirus (COVID-19) Vaccine total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Novel Coronavirus (COVID-19) Vaccine market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Inovio Pharmaceuticals, Takis Biotech (Evvivax), Zydus Cadila, Codagenix, Inc., GeoVax, Inc., Bravovax, Janssen Pharmaceutical Companies, Altimmune and Vaxart, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Novel Coronavirus (COVID-19) Vaccine market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Novel Coronavirus (COVID-19) Vaccine Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Novel Coronavirus (COVID-19) Vaccine Market, Segmentation by Type
DNA
RNA
Others
Global Novel Coronavirus (COVID-19) Vaccine Market, Segmentation by Application
Mild Symptom Patient
Critically Ill Patient
Companies Profiled:
Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise
Key Questions Answered
1. How big is the global Novel Coronavirus (COVID-19) Vaccine market?
2. What is the demand of the global Novel Coronavirus (COVID-19) Vaccine market?
3. What is the year over year growth of the global Novel Coronavirus (COVID-19) Vaccine market?
4. What is the total value of the global Novel Coronavirus (COVID-19) Vaccine market?
5. Who are the major players in the global Novel Coronavirus (COVID-19) Vaccine market?
Table of Contents
1 Supply Summary
1.1 Novel Coronavirus (COVID-19) Vaccine Introduction
1.2 World Novel Coronavirus (COVID-19) Vaccine Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Novel Coronavirus (COVID-19) Vaccine Total Market by Region (by Headquarter Location)
1.3.1 World Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2029)
1.3.3 China Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2029)
1.3.4 Europe Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2029)
1.3.5 Japan Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2029)
1.3.6 South Korea Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2029)
1.3.7 ASEAN Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2029)
1.3.8 India Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Novel Coronavirus (COVID-19) Vaccine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Novel Coronavirus (COVID-19) Vaccine Major Market Trends
2.1 World Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029)
2.2 World Novel Coronavirus (COVID-19) Vaccine Consumption Value by Region
2.2.1 World Novel Coronavirus (COVID-19) Vaccine Consumption Value by Region (2018-2023)
2.2.2 World Novel Coronavirus (COVID-19) Vaccine Consumption Value Forecast by Region (2024-2029)
2.3 United States Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029)
2.4 China Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029)
2.5 Europe Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029)
2.6 Japan Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029)
2.7 South Korea Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029)
2.8 ASEAN Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029)
2.9 India Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029)
3.1 World Novel Coronavirus (COVID-19) Vaccine Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Novel Coronavirus (COVID-19) Vaccine Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Novel Coronavirus (COVID-19) Vaccine in 2022
3.2.3 Global Concentration Ratios (CR8) for Novel Coronavirus (COVID-19) Vaccine in 2022
3.3 Novel Coronavirus (COVID-19) Vaccine Company Evaluation Quadrant
3.4 Novel Coronavirus (COVID-19) Vaccine Market: Overall Company Footprint Analysis
3.4.1 Novel Coronavirus (COVID-19) Vaccine Market: Region Footprint
3.4.2 Novel Coronavirus (COVID-19) Vaccine Market: Company Product Type Footprint
3.4.3 Novel Coronavirus (COVID-19) Vaccine Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4.1 United States VS China: Novel Coronavirus (COVID-19) Vaccine Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Novel Coronavirus (COVID-19) Vaccine Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Novel Coronavirus (COVID-19) Vaccine Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Novel Coronavirus (COVID-19) Vaccine Consumption Value Comparison
4.2.1 United States VS China: Novel Coronavirus (COVID-19) Vaccine Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Novel Coronavirus (COVID-19) Vaccine Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Novel Coronavirus (COVID-19) Vaccine Companies and Market Share, 2018-2023
4.3.1 United States Based Novel Coronavirus (COVID-19) Vaccine Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Novel Coronavirus (COVID-19) Vaccine Revenue, (2018-2023)
4.4 China Based Companies Novel Coronavirus (COVID-19) Vaccine Revenue and Market Share, 2018-2023
4.4.1 China Based Novel Coronavirus (COVID-19) Vaccine Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Novel Coronavirus (COVID-19) Vaccine Revenue, (2018-2023)
4.5 Rest of World Based Novel Coronavirus (COVID-19) Vaccine Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Novel Coronavirus (COVID-19) Vaccine Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Novel Coronavirus (COVID-19) Vaccine Revenue, (2018-2023)
5.1 World Novel Coronavirus (COVID-19) Vaccine Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 DNA
5.2.2 RNA
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023)
5.3.2 World Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2024-2029)
5.3.3 World Novel Coronavirus (COVID-19) Vaccine Market Size Market Share by Type (2018-2029)
6.1 World Novel Coronavirus (COVID-19) Vaccine Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Mild Symptom Patient
6.2.2 Critically Ill Patient
6.3 Market Segment by Application
6.3.1 World Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023)
6.3.2 World Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2024-2029)
6.3.3 World Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2029)
7.1 Inovio Pharmaceuticals
7.1.1 Inovio Pharmaceuticals Details
7.1.2 Inovio Pharmaceuticals Major Business
7.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Services
7.1.4 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Inovio Pharmaceuticals Recent Developments/Updates
7.1.6 Inovio Pharmaceuticals Competitive Strengths & Weaknesses
7.2 Takis Biotech (Evvivax)
7.2.1 Takis Biotech (Evvivax) Details
7.2.2 Takis Biotech (Evvivax) Major Business
7.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product and Services
7.2.4 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Takis Biotech (Evvivax) Recent Developments/Updates
7.2.6 Takis Biotech (Evvivax) Competitive Strengths & Weaknesses
7.3 Zydus Cadila
7.3.1 Zydus Cadila Details
7.3.2 Zydus Cadila Major Business
7.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product and Services
7.3.4 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Zydus Cadila Recent Developments/Updates
7.3.6 Zydus Cadila Competitive Strengths & Weaknesses
7.4 Codagenix, Inc.
7.4.1 Codagenix, Inc. Details
7.4.2 Codagenix, Inc. Major Business
7.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
7.4.4 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Codagenix, Inc. Recent Developments/Updates
7.4.6 Codagenix, Inc. Competitive Strengths & Weaknesses
7.5 GeoVax, Inc.
7.5.1 GeoVax, Inc. Details
7.5.2 GeoVax, Inc. Major Business
7.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
7.5.4 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 GeoVax, Inc. Recent Developments/Updates
7.5.6 GeoVax, Inc. Competitive Strengths & Weaknesses
7.6 Bravovax
7.6.1 Bravovax Details
7.6.2 Bravovax Major Business
7.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Product and Services
7.6.4 Bravovax Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Bravovax Recent Developments/Updates
7.6.6 Bravovax Competitive Strengths & Weaknesses
7.7 Janssen Pharmaceutical Companies
7.7.1 Janssen Pharmaceutical Companies Details
7.7.2 Janssen Pharmaceutical Companies Major Business
7.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product and Services
7.7.4 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Janssen Pharmaceutical Companies Recent Developments/Updates
7.7.6 Janssen Pharmaceutical Companies Competitive Strengths & Weaknesses
7.8 Altimmune
7.8.1 Altimmune Details
7.8.2 Altimmune Major Business
7.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Product and Services
7.8.4 Altimmune Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Altimmune Recent Developments/Updates
7.8.6 Altimmune Competitive Strengths & Weaknesses
7.9 Vaxart
7.9.1 Vaxart Details
7.9.2 Vaxart Major Business
7.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Product and Services
7.9.4 Vaxart Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Vaxart Recent Developments/Updates
7.9.6 Vaxart Competitive Strengths & Weaknesses
7.10 CanSino Biologics
7.10.1 CanSino Biologics Details
7.10.2 CanSino Biologics Major Business
7.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product and Services
7.10.4 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 CanSino Biologics Recent Developments/Updates
7.10.6 CanSino Biologics Competitive Strengths & Weaknesses
7.11 ExpreS2ion Biotechnologies ApS
7.11.1 ExpreS2ion Biotechnologies ApS Details
7.11.2 ExpreS2ion Biotechnologies ApS Major Business
7.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product and Services
7.11.4 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 ExpreS2ion Biotechnologies ApS Recent Developments/Updates
7.11.6 ExpreS2ion Biotechnologies ApS Competitive Strengths & Weaknesses
7.12 Clover Biopharmaceuticals
7.12.1 Clover Biopharmaceuticals Details
7.12.2 Clover Biopharmaceuticals Major Business
7.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Services
7.12.4 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Clover Biopharmaceuticals Recent Developments/Updates
7.12.6 Clover Biopharmaceuticals Competitive Strengths & Weaknesses
7.13 GSK
7.13.1 GSK Details
7.13.2 GSK Major Business
7.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Product and Services
7.13.4 GSK Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 GSK Recent Developments/Updates
7.13.6 GSK Competitive Strengths & Weaknesses
7.14 Vaxil Bio Ltd.
7.14.1 Vaxil Bio Ltd. Details
7.14.2 Vaxil Bio Ltd. Major Business
7.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product and Services
7.14.4 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Vaxil Bio Ltd. Recent Developments/Updates
7.14.6 Vaxil Bio Ltd. Competitive Strengths & Weaknesses
7.15 Generex
7.15.1 Generex Details
7.15.2 Generex Major Business
7.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Product and Services
7.15.4 Generex Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Generex Recent Developments/Updates
7.15.6 Generex Competitive Strengths & Weaknesses
7.16 Novavax, Inc.
7.16.1 Novavax, Inc. Details
7.16.2 Novavax, Inc. Major Business
7.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
7.16.4 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Novavax, Inc. Recent Developments/Updates
7.16.6 Novavax, Inc. Competitive Strengths & Weaknesses
7.17 Sanofi Pasteur
7.17.1 Sanofi Pasteur Details
7.17.2 Sanofi Pasteur Major Business
7.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product and Services
7.17.4 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Sanofi Pasteur Recent Developments/Updates
7.17.6 Sanofi Pasteur Competitive Strengths & Weaknesses
7.18 Baylor
7.18.1 Baylor Details
7.18.2 Baylor Major Business
7.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Product and Services
7.18.4 Baylor Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Baylor Recent Developments/Updates
7.18.6 Baylor Competitive Strengths & Weaknesses
7.19 iBio, Inc.
7.19.1 iBio, Inc. Details
7.19.2 iBio, Inc. Major Business
7.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
7.19.4 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.19.5 iBio, Inc. Recent Developments/Updates
7.19.6 iBio, Inc. Competitive Strengths & Weaknesses
7.20 Moderna, Inc.
7.20.1 Moderna, Inc. Details
7.20.2 Moderna, Inc. Major Business
7.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
7.20.4 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.20.5 Moderna, Inc. Recent Developments/Updates
7.20.6 Moderna, Inc. Competitive Strengths & Weaknesses
7.21 Curevac
7.21.1 Curevac Details
7.21.2 Curevac Major Business
7.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Product and Services
7.21.4 Curevac Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.21.5 Curevac Recent Developments/Updates
7.21.6 Curevac Competitive Strengths & Weaknesses
7.22 ImmunoPrecise
7.22.1 ImmunoPrecise Details
7.22.2 ImmunoPrecise Major Business
7.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product and Services
7.22.4 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023)
7.22.5 ImmunoPrecise Recent Developments/Updates
7.22.6 ImmunoPrecise Competitive Strengths & Weaknesses
8.1 Novel Coronavirus (COVID-19) Vaccine Industry Chain
8.2 Novel Coronavirus (COVID-19) Vaccine Upstream Analysis
8.3 Novel Coronavirus (COVID-19) Vaccine Midstream Analysis
8.4 Novel Coronavirus (COVID-19) Vaccine Downstream Analysis
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. World Novel Coronavirus (COVID-19) Vaccine Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Novel Coronavirus (COVID-19) Vaccine Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Novel Coronavirus (COVID-19) Vaccine Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Novel Coronavirus (COVID-19) Vaccine Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Novel Coronavirus (COVID-19) Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Novel Coronavirus (COVID-19) Vaccine Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Novel Coronavirus (COVID-19) Vaccine Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Novel Coronavirus (COVID-19) Vaccine Players in 2022
Table 12. World Novel Coronavirus (COVID-19) Vaccine Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Novel Coronavirus (COVID-19) Vaccine Company Evaluation Quadrant
Table 14. Head Office of Key Novel Coronavirus (COVID-19) Vaccine Player
Table 15. Novel Coronavirus (COVID-19) Vaccine Market: Company Product Type Footprint
Table 16. Novel Coronavirus (COVID-19) Vaccine Market: Company Product Application Footprint
Table 17. Novel Coronavirus (COVID-19) Vaccine Mergers & Acquisitions Activity
Table 18. United States VS China Novel Coronavirus (COVID-19) Vaccine Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Novel Coronavirus (COVID-19) Vaccine Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Novel Coronavirus (COVID-19) Vaccine Companies, Headquarters (States, Country)
Table 21. United States Based Companies Novel Coronavirus (COVID-19) Vaccine Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Novel Coronavirus (COVID-19) Vaccine Revenue Market Share (2018-2023)
Table 23. China Based Novel Coronavirus (COVID-19) Vaccine Companies, Headquarters (Province, Country)
Table 24. China Based Companies Novel Coronavirus (COVID-19) Vaccine Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Novel Coronavirus (COVID-19) Vaccine Revenue Market Share (2018-2023)
Table 26. Rest of World Based Novel Coronavirus (COVID-19) Vaccine Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Novel Coronavirus (COVID-19) Vaccine Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Novel Coronavirus (COVID-19) Vaccine Revenue Market Share (2018-2023)
Table 29. World Novel Coronavirus (COVID-19) Vaccine Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) & (USD Million)
Table 31. World Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2024-2029) & (USD Million)
Table 32. World Novel Coronavirus (COVID-19) Vaccine Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) & (USD Million)
Table 34. World Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2024-2029) & (USD Million)
Table 35. Inovio Pharmaceuticals Basic Information, Area Served and Competitors
Table 36. Inovio Pharmaceuticals Major Business
Table 37. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 38. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Inovio Pharmaceuticals Recent Developments/Updates
Table 40. Inovio Pharmaceuticals Competitive Strengths & Weaknesses
Table 41. Takis Biotech (Evvivax) Basic Information, Area Served and Competitors
Table 42. Takis Biotech (Evvivax) Major Business
Table 43. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 44. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Takis Biotech (Evvivax) Recent Developments/Updates
Table 46. Takis Biotech (Evvivax) Competitive Strengths & Weaknesses
Table 47. Zydus Cadila Basic Information, Area Served and Competitors
Table 48. Zydus Cadila Major Business
Table 49. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 50. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Zydus Cadila Recent Developments/Updates
Table 52. Zydus Cadila Competitive Strengths & Weaknesses
Table 53. Codagenix, Inc. Basic Information, Area Served and Competitors
Table 54. Codagenix, Inc. Major Business
Table 55. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 56. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Codagenix, Inc. Recent Developments/Updates
Table 58. Codagenix, Inc. Competitive Strengths & Weaknesses
Table 59. GeoVax, Inc. Basic Information, Area Served and Competitors
Table 60. GeoVax, Inc. Major Business
Table 61. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 62. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. GeoVax, Inc. Recent Developments/Updates
Table 64. GeoVax, Inc. Competitive Strengths & Weaknesses
Table 65. Bravovax Basic Information, Area Served and Competitors
Table 66. Bravovax Major Business
Table 67. Bravovax Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 68. Bravovax Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Bravovax Recent Developments/Updates
Table 70. Bravovax Competitive Strengths & Weaknesses
Table 71. Janssen Pharmaceutical Companies Basic Information, Area Served and Competitors
Table 72. Janssen Pharmaceutical Companies Major Business
Table 73. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 74. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Janssen Pharmaceutical Companies Recent Developments/Updates
Table 76. Janssen Pharmaceutical Companies Competitive Strengths & Weaknesses
Table 77. Altimmune Basic Information, Area Served and Competitors
Table 78. Altimmune Major Business
Table 79. Altimmune Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 80. Altimmune Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Altimmune Recent Developments/Updates
Table 82. Altimmune Competitive Strengths & Weaknesses
Table 83. Vaxart Basic Information, Area Served and Competitors
Table 84. Vaxart Major Business
Table 85. Vaxart Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 86. Vaxart Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Vaxart Recent Developments/Updates
Table 88. Vaxart Competitive Strengths & Weaknesses
Table 89. CanSino Biologics Basic Information, Area Served and Competitors
Table 90. CanSino Biologics Major Business
Table 91. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 92. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. CanSino Biologics Recent Developments/Updates
Table 94. CanSino Biologics Competitive Strengths & Weaknesses
Table 95. ExpreS2ion Biotechnologies ApS Basic Information, Area Served and Competitors
Table 96. ExpreS2ion Biotechnologies ApS Major Business
Table 97. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 98. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. ExpreS2ion Biotechnologies ApS Recent Developments/Updates
Table 100. ExpreS2ion Biotechnologies ApS Competitive Strengths & Weaknesses
Table 101. Clover Biopharmaceuticals Basic Information, Area Served and Competitors
Table 102. Clover Biopharmaceuticals Major Business
Table 103. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 104. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Clover Biopharmaceuticals Recent Developments/Updates
Table 106. Clover Biopharmaceuticals Competitive Strengths & Weaknesses
Table 107. GSK Basic Information, Area Served and Competitors
Table 108. GSK Major Business
Table 109. GSK Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 110. GSK Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. GSK Recent Developments/Updates
Table 112. GSK Competitive Strengths & Weaknesses
Table 113. Vaxil Bio Ltd. Basic Information, Area Served and Competitors
Table 114. Vaxil Bio Ltd. Major Business
Table 115. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 116. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Vaxil Bio Ltd. Recent Developments/Updates
Table 118. Vaxil Bio Ltd. Competitive Strengths & Weaknesses
Table 119. Generex Basic Information, Area Served and Competitors
Table 120. Generex Major Business
Table 121. Generex Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 122. Generex Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Generex Recent Developments/Updates
Table 124. Generex Competitive Strengths & Weaknesses
Table 125. Novavax, Inc. Basic Information, Area Served and Competitors
Table 126. Novavax, Inc. Major Business
Table 127. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 128. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Novavax, Inc. Recent Developments/Updates
Table 130. Novavax, Inc. Competitive Strengths & Weaknesses
Table 131. Sanofi Pasteur Basic Information, Area Served and Competitors
Table 132. Sanofi Pasteur Major Business
Table 133. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 134. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Sanofi Pasteur Recent Developments/Updates
Table 136. Sanofi Pasteur Competitive Strengths & Weaknesses
Table 137. Baylor Basic Information, Area Served and Competitors
Table 138. Baylor Major Business
Table 139. Baylor Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 140. Baylor Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 141. Baylor Recent Developments/Updates
Table 142. Baylor Competitive Strengths & Weaknesses
Table 143. iBio, Inc. Basic Information, Area Served and Competitors
Table 144. iBio, Inc. Major Business
Table 145. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 146. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 147. iBio, Inc. Recent Developments/Updates
Table 148. iBio, Inc. Competitive Strengths & Weaknesses
Table 149. Moderna, Inc. Basic Information, Area Served and Competitors
Table 150. Moderna, Inc. Major Business
Table 151. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 152. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 153. Moderna, Inc. Recent Developments/Updates
Table 154. Moderna, Inc. Competitive Strengths & Weaknesses
Table 155. Curevac Basic Information, Area Served and Competitors
Table 156. Curevac Major Business
Table 157. Curevac Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 158. Curevac Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 159. Curevac Recent Developments/Updates
Table 160. ImmunoPrecise Basic Information, Area Served and Competitors
Table 161. ImmunoPrecise Major Business
Table 162. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product and Services
Table 163. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 164. Global Key Players of Novel Coronavirus (COVID-19) Vaccine Upstream (Raw Materials)
Table 165. Novel Coronavirus (COVID-19) Vaccine Typical Customers
List of Figure
Figure 1. Novel Coronavirus (COVID-19) Vaccine Picture
Figure 2. World Novel Coronavirus (COVID-19) Vaccine Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Novel Coronavirus (COVID-19) Vaccine Total Market Size (2018-2029) & (USD Million)
Figure 4. World Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Novel Coronavirus (COVID-19) Vaccine Revenue (2018-2029) & (USD Million)
Figure 13. Novel Coronavirus (COVID-19) Vaccine Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 16. World Novel Coronavirus (COVID-19) Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 18. China Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 23. India Novel Coronavirus (COVID-19) Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Novel Coronavirus (COVID-19) Vaccine by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Novel Coronavirus (COVID-19) Vaccine Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Novel Coronavirus (COVID-19) Vaccine Markets in 2022
Figure 27. United States VS China: Novel Coronavirus (COVID-19) Vaccine Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Novel Coronavirus (COVID-19) Vaccine Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Novel Coronavirus (COVID-19) Vaccine Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Novel Coronavirus (COVID-19) Vaccine Market Size Market Share by Type in 2022
Figure 31. DNA
Figure 32. RNA
Figure 33. Others
Figure 34. World Novel Coronavirus (COVID-19) Vaccine Market Size Market Share by Type (2018-2029)
Figure 35. World Novel Coronavirus (COVID-19) Vaccine Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Novel Coronavirus (COVID-19) Vaccine Market Size Market Share by Application in 2022
Figure 37. Mild Symptom Patient
Figure 38. Critically Ill Patient
Figure 39. Novel Coronavirus (COVID-19) Vaccine Industrial Chain
Figure 40. Methodology
Figure 41. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Inovio Pharmaceuticals Takis Biotech (Evvivax) Zydus Cadila Codagenix, Inc. GeoVax, Inc. Bravovax Janssen Pharmaceutical Companies Altimmune Vaxart CanSino Biologics ExpreS2ion Biotechnologies ApS Clover Biopharmaceuticals GSK Vaxil Bio Ltd. Generex Novavax, Inc. Sanofi Pasteur Baylor iBio, Inc. Moderna, Inc. Curevac ImmunoPrecise
Related Reports
06 Sep 2023
New Technology
Product Tags
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
